TDMS Study 05180-06 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest GALLIUM ARSENIDE DATE: 02/17/99
EXPERIMENT: 05180 TEST: 06 TIME: 08:15:51
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: NO1-ES-25335 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 62033B
PATHOLOGIST: GRUMBEIN, S. CAS: 1303-00-0000
------------------------------------------------------------------------------------------------------------------------------------
2 YEAR CHRONIC RATS
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest GALLIUM ARSENIDE DATE: 02/17/99
EXPERIMENT: 05180 TEST: 06 TIME: 08:15:51
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-25335 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 62033B
PATHOLOGIST: GRUMBEIN, S. CAS: 1303-00-0000
Rats(FISCHER 344)
-----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE
BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES
ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.
---------------
Adrenal Medulla
Brain
Clitoral/Preputial Gland
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Ovary
Pancreas
Pituitary Gland
Prostate
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest GALLIUM ARSENIDE DATE: 02/17/99
EXPERIMENT: 05180 TEST: 06 TIME: 08:15:51
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-25335 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 62033B
PATHOLOGIST: GRUMBEIN, S. CAS: 1303-00-0000
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF GALLIUM ARSENIDE
===============================================================
Male Rats
------------
Organ Morphology
----- ----------
Clitoral/Preputial Gland Adenoma
All Organs Hemangioma
Leukemia: Lymphocytic, Monocytic, Mononuclear, or Undifferentiated
Malignant Tumors
===============================================================
Female Rats
------------
Organ Morphology
----- ----------
Adrenal Medulla Pheochromocytoma Benign
Pheochromocytoma: Benign, Complex, Malignant, NOS
Islets, Pancreatic Carcinoma or Adenoma
Lung Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Mammary Gland Fibroadenoma
Fibroma, Fibroadenoma or Adenoma
Fibroma, Fibroadenoma, Carcinoma, or Adenoma
Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma
Thyroid Gland: C-Cell Adenoma
All Organs Leukemia: Lymphocytic, Monocytic, Mononuclear, or Undifferentiated
Malignant Tumors
Malignant and Benign Tumors
===============================================================
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 1
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 16/50 (32%) 12/49 (24%) 22/49 (45%) 13/50 (26%) |4/50 (8%) 5/49 (10%) 6/50 (12%) 13/49 (27%) |
|POLY-3 ADJUSTED (b)| 40.8% 33.0% 54.8% 35.3% |9.9% 13.3% 16.0% 36.0% |
|TERMINAL (d) | 5/13 (39%) 4/13 (31%) 9/15 (60%) 7/13 (54%) |1/19 (5%) 2/16 (13%) 5/21 (24%) 4/11 (36%) |
|FIRST INCIDENCE | 567 614 590 547 |506 695 674 564 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.347N P=0.342N P=0.284 P=0.376N |P<0.001 ** P=0.447 P=0.390 P=0.002 ** |
|POLY 3 | P=0.297N P=0.314N P=0.140 P=0.395N |P<0.001 ** P=0.455 P=0.321 P=0.005 ** |
|POLY 1.5 | P=0.271N P=0.303N P=0.133 P=0.368N |P=0.002 ** P=0.469 P=0.336 P=0.007 ** |
|POLY 6 | P=0.344N P=0.316N P=0.162 P=0.434N |P<0.001 ** P=0.441 P=0.309 P=0.003 ** |
|LOGISTIC REGRESSION| P=0.314N P=0.334N P=0.165 P=0.404N |P<0.001 ** P=0.463 P=0.329 P=0.007 ** |
|COCH-ARM / FISHERS | P=0.251N P=0.272N P=0.133 P=0.330N |P=0.004 ** P=0.487 P=0.370 P=0.014 * |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Malignant |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/49 (0%) 3/49 (6%) 1/50 (2%) |0/50 (0%) 1/49 (2%) 0/50 (0%) 0/49 (0%) |
|POLY-3 ADJUSTED (b)| 5.4% 0.0% 8.0% 2.9% |0.0% 2.7% 0.0% 0.0% |
|TERMINAL (d) | 1/13 (8%) 0/13 (0%) 2/15 (13%) 0/13 (0%) |0/19 (0%) 1/16 (6%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 671 --- 601 713 |--- 734 (T) --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.549N P=0.259N P=0.555 P=0.527N |P=0.768N P=0.466 (e) (e) |
|POLY 3 | P=0.537N P=0.254N P=0.508 P=0.519N |P=0.682N P=0.489 (e) (e) |
|POLY 1.5 | P=0.532N P=0.250N P=0.500 P=0.512N |P=0.677N P=0.492 (e) (e) |
|POLY 6 | P=0.542N P=0.258N P=0.521 P=0.527N |P=0.689N P=0.485 (e) (e) |
|LOGISTIC REGRESSION| P=0.554N P=0.256N P=0.517 P=0.524N |(e) P=0.466 (e) (e) |
|COCH-ARM / FISHERS | P=0.528N P=0.253N P=0.490 P=0.500N |P=0.671N P=0.495 (e) (e) |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 2
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma: Benign, Complex, Malignant, NOS |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 16/50 (32%) 12/49 (24%) 23/49 (47%) 14/50 (28%) |4/50 (8%) 6/49 (12%) 6/50 (12%) 13/49 (27%) |
|POLY-3 ADJUSTED (b)| 40.8% 33.0% 56.7% 38.0% |9.9% 16.0% 16.0% 36.0% |
|TERMINAL (d) | 5/13 (39%) 4/13 (31%) 9/15 (60%) 7/13 (54%) |1/19 (5%) 3/16 (19%) 5/21 (24%) 4/11 (36%) |
|FIRST INCIDENCE | 567 614 590 547 |506 695 674 564 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.418N P=0.342N P=0.233 P=0.459N |P<0.001 ** P=0.317 P=0.390 P=0.002 ** |
|POLY 3 | P=0.380N P=0.314N P=0.103 P=0.492N |P=0.002 ** P=0.323 P=0.321 P=0.005 ** |
|POLY 1.5 | P=0.347N P=0.303N P=0.096 P=0.459N |P=0.003 ** P=0.338 P=0.336 P=0.007 ** |
|POLY 6 | P=0.438N P=0.316N P=0.127 P=0.536N |P=0.002 ** P=0.308 P=0.309 P=0.003 ** |
|LOGISTIC REGRESSION| P=0.395N P=0.334N P=0.115 P=0.502N |P<0.001 ** P=0.328 P=0.329 P=0.007 ** |
|COCH-ARM / FISHERS | P=0.318N P=0.272N P=0.094 P=0.414N |P=0.006 ** P=0.357 P=0.370 P=0.014 * |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Bone |
| Osteosarcoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 2/50 (4%) 0/50 (0%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 2.7% 0.0% 5.2% 0.0% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 567 --- 562 --- |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.427N P=0.510N P=0.512 P=0.515N |(e) (e) (e) (e) |
|POLY 3 | P=0.402N P=0.517N P=0.511 P=0.513N |(e) (e) (e) (e) |
|POLY 1.5 | P=0.400N P=0.512N P=0.506 P=0.508N |(e) (e) (e) (e) |
|POLY 6 | P=0.406N P=0.523N P=0.521 P=0.519N |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.395N P=0.454N P=0.489 P=0.466N |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.400N P=0.500N P=0.500 P=0.500N |(e) (e) (e) (e) |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 3
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Clitoral/Preputial Gland |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/49 (4%) 3/50 (6%) 6/49 (12%) |8/50 (16%) 9/48 (19%) 7/47 (15%) 4/48 (8%) |
|POLY-3 ADJUSTED (b)| 0.0% 5.9% 7.8% 16.7% |19.6% 23.5% 19.7% 11.9% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 1/15 (7%) 3/13 (23%) |4/19 (21%) 4/16 (25%) 5/20 (25%) 0/10 (0%) |
|FIRST INCIDENCE | --- 574 604 520 |581 590 631 632 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.017 * P=0.237 P=0.141 P=0.018 * |P=0.333N P=0.413 P=0.502N P=0.424N |
|POLY 3 | P=0.016 * P=0.218 P=0.126 P=0.013 * |P=0.174N P=0.444 P=0.610 P=0.279N |
|POLY 1.5 | P=0.016 * P=0.222 P=0.122 P=0.013 * |P=0.150N P=0.454 P=0.597N P=0.247N |
|POLY 6 | P=0.015 * P=0.215 P=0.132 P=0.012 * |P=0.205N P=0.434 P=0.601 P=0.317N |
|LOGISTIC REGRESSION| P=0.017 * P=0.224 P=0.120 P=0.015 * |P=0.178N P=0.445 P=0.605N P=0.265N |
|COCH-ARM / FISHERS | P=0.017 * P=0.242 P=0.121 P=0.012 * |P=0.113N P=0.463 P=0.552N P=0.199N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Clitoral/Preputial Gland |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 4/49 (8%) 5/50 (10%) 4/49 (8%) |3/50 (6%) 2/48 (4%) 2/47 (4%) 2/48 (4%) |
|POLY-3 ADJUSTED (b)| 10.6% 11.7% 12.8% 11.1% |7.5% 5.3% 5.7% 6.1% |
|TERMINAL (d) | 1/13 (8%) 2/13 (15%) 0/15 (0%) 1/13 (8%) |2/19 (11%) 1/16 (6%) 2/20 (10%) 1/10 (10%) |
|FIRST INCIDENCE | 534 567 590 540 |582 559 734 (T) 684 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.601 P=0.616 P=0.549 P=0.605 |P=0.540 P=0.561N P=0.490N P=0.662 |
|POLY 3 | P=0.582N P=0.592 P=0.525 P=0.621 |P=0.623N P=0.527N P=0.563N P=0.589N |
|POLY 1.5 | P=0.577N P=0.603 P=0.512 P=0.624 |P=0.600N P=0.522N P=0.553N P=0.563N |
|POLY 6 | P=0.589N P=0.582 P=0.550 P=0.622 |P=0.631 P=0.533N P=0.570N P=0.620N |
|LOGISTIC REGRESSION| P=0.575N P=0.609 P=0.497 P=0.636 |P=0.636N P=0.520N P=0.559N P=0.601N |
|COCH-ARM / FISHERS | P=0.575N P=0.631 P=0.500 P=0.631 |P=0.562N P=0.520N P=0.530N P=0.520N |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 4
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Clitoral/Preputial Gland |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 6/49 (12%) 8/50 (16%) 10/49 (20%) |11/50 (22%) 11/48 (23%) 9/47 (19%) 6/48 (13%) |
|POLY-3 ADJUSTED (b)| 10.6% 17.3% 20.0% 26.8% |26.7% 28.3% 25.3% 17.8% |
|TERMINAL (d) | 1/13 (8%) 3/13 (23%) 1/15 (7%) 4/13 (31%) |6/19 (32%) 5/16 (31%) 7/20 (35%) 1/10 (10%) |
|FIRST INCIDENCE | 534 567 590 520 |581 559 631 632 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.086 P=0.349 P=0.235 P=0.073 |P=0.410N P=0.482 P=0.398N P=0.446N |
|POLY 3 | P=0.092 P=0.315 P=0.202 P=0.062 |P=0.193N P=0.536 P=0.552N P=0.260N |
|POLY 1.5 | P=0.093 P=0.327 P=0.189 P=0.063 |P=0.161N P=0.545 P=0.523N P=0.221N |
|POLY 6 | P=0.089 P=0.307 P=0.228 P=0.061 |P=0.233N P=0.528 P=0.577N P=0.307N |
|LOGISTIC REGRESSION| P=0.092 P=0.330 P=0.176 P=0.067 |P=0.197N P=0.538 P=0.527N P=0.251N |
|COCH-ARM / FISHERS | P=0.093 P=0.357 P=0.178 P=0.068 |P=0.116N P=0.553 P=0.463N P=0.165N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/48 (4%) 1/49 (2%) 2/50 (4%) 2/50 (4%) |1/50 (2%) 0/50 (0%) 0/50 (0%) 2/49 (4%) |
|POLY-3 ADJUSTED (b)| 5.6% 2.9% 5.3% 5.6% |2.5% 0.0% 0.0% 5.8% |
|TERMINAL (d) | 1/13 (8%) 1/13 (8%) 0/15 (0%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 671 733 (T) 704 601 |685 --- --- 691 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.539 P=0.520N P=0.661N P=0.660 |P=0.127 P=0.480N P=0.539N P=0.443 |
|POLY 3 | P=0.572 P=0.517N P=0.676N P=0.695 |P=0.139 P=0.507N P=0.513N P=0.449 |
|POLY 1.5 | P=0.573 P=0.508N P=0.677N P=0.690N |P=0.145 P=0.504N P=0.509N P=0.465 |
|POLY 6 | P=0.573 P=0.528N P=0.674N P=0.692 |P=0.134 P=0.510N P=0.515N P=0.432 |
|LOGISTIC REGRESSION| P=0.554 P=0.528N P=0.670N P=0.694N |P=0.130 P=0.504N P=0.509N P=0.445 |
|COCH-ARM / FISHERS | P=0.577 P=0.492N P=0.676N P=0.676N |P=0.155 P=0.500N P=0.500N P=0.492 |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 5
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/48 (0%) 3/49 (6%) 0/50 (0%) 1/50 (2%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 1/49 (2%) |
|POLY-3 ADJUSTED (b)| 0.0% 8.7% 0.0% 2.9% |0.0% 0.0% 0.0% 2.9% |
|TERMINAL (d) | 0/13 (0%) 2/13 (15%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | --- 532 --- 733 (T) |--- --- --- 688 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.688N P=0.117 (e) P=0.500 |P=0.231 (e) (e) P=0.468 |
|POLY 3 | P=0.691N P=0.112 (e) P=0.496 |P=0.237 (e) (e) P=0.471 |
|POLY 1.5 | P=0.681N P=0.116 (e) P=0.501 |P=0.243 (e) (e) P=0.480 |
|POLY 6 | P=0.702N P=0.109 (e) P=0.491 |P=0.231 (e) (e) P=0.461 |
|LOGISTIC REGRESSION| P=0.682N P=0.115 (e) P=0.500 |P=0.234 (e) (e) P=0.469 |
|COCH-ARM / FISHERS | P=0.664N P=0.125 (e) P=0.510 |P=0.253 (e) (e) P=0.495 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/48 (4%) 4/49 (8%) 2/50 (4%) 3/50 (6%) |1/50 (2%) 0/50 (0%) 0/50 (0%) 3/49 (6%) |
|POLY-3 ADJUSTED (b)| 5.6% 11.5% 5.3% 8.4% |2.5% 0.0% 0.0% 8.7% |
|TERMINAL (d) | 1/13 (8%) 3/13 (23%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 671 532 704 601 |685 --- --- 688 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.547 P=0.317 P=0.661N P=0.468 |P=0.028 * P=0.480N P=0.539N P=0.252 |
|POLY 3 | P=0.570 P=0.321 P=0.676N P=0.499 |P=0.032 * P=0.507N P=0.513N P=0.256 |
|POLY 1.5 | P=0.577 P=0.329 P=0.677N P=0.506 |P=0.034 * P=0.504N P=0.509N P=0.270 |
|POLY 6 | P=0.564 P=0.310 P=0.674N P=0.493 |P=0.030 * P=0.510N P=0.515N P=0.241 |
|LOGISTIC REGRESSION| P=0.562 P=0.308 P=0.670N P=0.491 |P=0.028 * P=0.504N P=0.509N P=0.250 |
|COCH-ARM / FISHERS | P=0.590 P=0.349 P=0.676N P=0.520 |P=0.039 * P=0.500N P=0.500N P=0.301 |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 6
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Kidney: Renal Tubule |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/49 (4%) 0/50 (0%) 0/50 (0%) 3/50 (6%) |0/50 (0%) 0/50 (0%) 1/50 (2%) 0/49 (0%) |
|POLY-3 ADJUSTED (b)| 5.4% 0.0% 0.0% 8.5% |0.0% 0.0% 2.7% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 2/13 (15%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | 590 --- --- 604 |--- --- 734 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.099 P=0.257N P=0.227N P=0.488 |P=0.841N (e) P=0.520 (e) |
|POLY 3 | P=0.103 P=0.253N P=0.231N P=0.481 |P=0.764N (e) P=0.488 (e) |
|POLY 1.5 | P=0.104 P=0.246N P=0.232N P=0.493 |P=0.758N (e) P=0.491 (e) |
|POLY 6 | P=0.101 P=0.261N P=0.231N P=0.469 |P=0.771N (e) P=0.487 (e) |
|LOGISTIC REGRESSION| P=0.100 P=0.230N P=0.235N P=0.489 |(e) (e) P=0.520 (e) |
|COCH-ARM / FISHERS | P=0.106 P=0.242N P=0.242N P=0.510 |P=0.747N (e) P=0.500 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 2/50 (4%) 0/50 (0%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 2.7% 2.9% 5.3% 0.0% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 1/15 (7%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 726 733 (T) 698 --- |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.296N P=0.745 P=0.546 P=0.514N |(e) (e) (e) (e) |
|POLY 3 | P=0.302N P=0.745 P=0.509 P=0.510N |(e) (e) (e) (e) |
|POLY 1.5 | P=0.298N P=0.750 P=0.505 P=0.506N |(e) (e) (e) (e) |
|POLY 6 | P=0.306N P=0.742 P=0.518 P=0.514N |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.300N P=0.751 P=0.526 P=0.508N |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.294N P=0.753N P=0.500 P=0.500N |(e) (e) (e) (e) |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 7
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, |
| or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 2/50 (4%) 0/50 (0%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 2.7% 2.9% 5.3% 0.0% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 1/15 (7%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 726 733 (T) 698 --- |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.296N P=0.745 P=0.546 P=0.514N |(e) (e) (e) (e) |
|POLY 3 | P=0.302N P=0.745 P=0.509 P=0.510N |(e) (e) (e) (e) |
|POLY 1.5 | P=0.298N P=0.750 P=0.505 P=0.506N |(e) (e) (e) (e) |
|POLY 6 | P=0.306N P=0.742 P=0.518 P=0.514N |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.300N P=0.751 P=0.526 P=0.508N |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.294N P=0.753N P=0.500 P=0.500N |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/49 (0%) 3/50 (6%) 2/50 (4%) |0/50 (0%) 0/50 (0%) 2/50 (4%) 7/50 (14%) |
|POLY-3 ADJUSTED (b)| 2.7% 0.0% 8.0% 5.7% |0.0% 0.0% 5.3% 19.7% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 3/15 (20%) 2/13 (15%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 2/11 (18%) |
|FIRST INCIDENCE | 688 --- 733 (T) 733 (T) |--- --- 646 556 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.412 P=0.490N P=0.357 P=0.506 |P<0.001 ** (e) P=0.244 P=0.003 ** |
|POLY 3 | P=0.421 P=0.516N P=0.310 P=0.481 |P<0.001 ** (e) P=0.225 P=0.004 ** |
|POLY 1.5 | P=0.426 P=0.512N P=0.308 P=0.488 |P<0.001 ** (e) P=0.228 P=0.005 ** |
|POLY 6 | P=0.416 P=0.520N P=0.314 P=0.473 |P<0.001 ** (e) P=0.225 P=0.003 ** |
|LOGISTIC REGRESSION| P=0.410 P=0.517N P=0.328 P=0.480 |P<0.001 ** (e) P=0.226 P=0.005 ** |
|COCH-ARM / FISHERS | P=0.431 P=0.505N P=0.309 P=0.500 |P<0.001 ** (e) P=0.247 P=0.006 ** |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 8
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/49 (0%) 2/50 (4%) 1/50 (2%) |0/50 (0%) 0/50 (0%) 2/50 (4%) 3/50 (6%) |
|POLY-3 ADJUSTED (b)| 5.4% 0.0% 5.3% 2.9% |0.0% 0.0% 5.4% 8.6% |
|TERMINAL (d) | 1/13 (8%) 0/13 (0%) 1/15 (7%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 2/21 (10%) 1/11 (9%) |
|FIRST INCIDENCE | 567 --- 722 733 (T) |--- --- 734 (T) 677 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.629N P=0.245N P=0.659N P=0.509N |P=0.024 * (e) P=0.259 P=0.077 |
|POLY 3 | P=0.617N P=0.256N P=0.692N P=0.523N |P=0.053 (e) P=0.224 P=0.097 |
|POLY 1.5 | P=0.613N P=0.251N P=0.693N P=0.514N |P=0.059 (e) P=0.227 P=0.104 |
|POLY 6 | P=0.623N P=0.261N P=0.689N P=0.533N |P=0.048 * (e) P=0.221 P=0.089 |
|LOGISTIC REGRESSION| P=0.632N P=0.245N P=0.683N P=0.518N |P=0.037 * (e) P=0.259 P=0.087 |
|COCH-ARM / FISHERS | P=0.609N P=0.253N P=0.691N P=0.500N |P=0.070 (e) P=0.247 P=0.121 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 0/49 (0%) 5/50 (10%) 3/50 (6%) |0/50 (0%) 0/50 (0%) 4/50 (8%) 9/50 (18%) |
|POLY-3 ADJUSTED (b)| 8.0% 0.0% 13.3% 8.6% |0.0% 0.0% 10.7% 25.0% |
|TERMINAL (d) | 1/13 (8%) 0/13 (0%) 4/15 (27%) 3/13 (23%) |0/19 (0%) 0/17 (0%) 3/21 (14%) 2/11 (18%) |
|FIRST INCIDENCE | 567 --- 722 733 (T) |--- --- 646 556 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.479 P=0.124N P=0.423 P=0.663 |P<0.001 ** (e) P=0.071 P<0.001 ** |
|POLY 3 | P=0.490 P=0.134N P=0.357 P=0.632 |P<0.001 ** (e) P=0.053 P<0.001 ** |
|POLY 1.5 | P=0.498 P=0.130N P=0.357 P=0.644 |P<0.001 ** (e) P=0.055 P<0.001 ** |
|POLY 6 | P=0.480 P=0.139N P=0.357 P=0.617 |P<0.001 ** (e) P=0.052 P<0.001 ** |
|LOGISTIC REGRESSION| P=0.471 P=0.130N P=0.387 P=0.634 |P<0.001 ** (e) P=0.054 P<0.001 ** |
|COCH-ARM / FISHERS | P=0.505 P=0.125N P=0.357 P=0.661N |P<0.001 ** (e) P=0.059 P<0.001 ** |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 9
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) |8/50 (16%) 3/50 (6%) 7/50 (14%) 5/50 (10%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 2.9% |19.8% 7.7% 18.7% 14.2% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |4/19 (21%) 1/17 (6%) 6/21 (29%) 1/11 (9%) |
|FIRST INCIDENCE | --- --- --- 668 |589 559 701 632 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.248 (e) (e) P=0.483 |P=0.446 P=0.130N P=0.477N P=0.523N |
|POLY 3 | P=0.256 (e) (e) P=0.491 |P=0.549N P=0.105N P=0.569N P=0.368N |
|POLY 1.5 | P=0.257 (e) (e) P=0.494 |P=0.516N P=0.102N P=0.546N P=0.333N |
|POLY 6 | P=0.256 (e) (e) P=0.490 |P=0.588N P=0.108N P=0.594N P=0.411N |
|LOGISTIC REGRESSION| P=0.252 (e) (e) P=0.492 |P=0.588N P=0.106N P=0.558N P=0.392N |
|COCH-ARM / FISHERS | P=0.257 (e) (e) P=0.500 |P=0.457N P=0.100N P=0.500N P=0.277N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) |8/50 (16%) 3/50 (6%) 7/50 (14%) 6/50 (12%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 2.9% |19.8% 7.7% 18.7% 16.9% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |4/19 (21%) 1/17 (6%) 6/21 (29%) 1/11 (9%) |
|FIRST INCIDENCE | --- --- --- 668 |589 559 701 632 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.248 (e) (e) P=0.483 |P=0.292 P=0.130N P=0.477N P=0.579 |
|POLY 3 | P=0.256 (e) (e) P=0.491 |P=0.488 P=0.105N P=0.569N P=0.491N |
|POLY 1.5 | P=0.257 (e) (e) P=0.494 |P=0.520 P=0.102N P=0.546N P=0.453N |
|POLY 6 | P=0.256 (e) (e) P=0.490 |P=0.454 P=0.108N P=0.594N P=0.534N |
|LOGISTIC REGRESSION| P=0.252 (e) (e) P=0.492 |P=0.449 P=0.106N P=0.558N P=0.518N |
|COCH-ARM / FISHERS | P=0.257 (e) (e) P=0.500 |P=0.578 P=0.100N P=0.500N P=0.387N |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 10
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroadenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 3/50 (6%) 2/50 (4%) |26/50 (52%) 31/50 (62%) 29/50 (58%) 31/50 (62%) |
|POLY-3 ADJUSTED (b)| 0.0% 5.8% 7.9% 5.6% |59.2% 71.3% 68.0% 74.3% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 0/15 (0%) 1/13 (8%) |11/19 (58%) 13/17 (77%) 16/21 (76%) 7/11 (64%) |
|FIRST INCIDENCE | --- 660 601 422 |497 422 339 418 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.516 P=0.217 P=0.150 P=0.240 |P=0.018 * P=0.173 P=0.391 P=0.025 * |
|POLY 3 | P=0.521 P=0.222 P=0.125 P=0.230 |P=0.184 P=0.152 P=0.252 P=0.090 |
|POLY 1.5 | P=0.524 P=0.226 P=0.122 P=0.233 |P=0.223 P=0.178 P=0.280 P=0.122 |
|POLY 6 | P=0.519 P=0.219 P=0.131 P=0.228 |P=0.158 P=0.128 P=0.223 P=0.069 |
|LOGISTIC REGRESSION| P=0.524 P=0.217 P=0.122 P=0.266 |P=0.172 P=0.172 P=0.264 P=0.096 |
|COCH-ARM / FISHERS | P=0.527 P=0.247 P=0.121 P=0.247 |P=0.329 P=0.210 P=0.344 P=0.210 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 3/50 (6%) 2/50 (4%) |26/50 (52%) 31/50 (62%) 29/50 (58%) 31/50 (62%) |
|POLY-3 ADJUSTED (b)| 0.0% 5.8% 7.9% 5.6% |59.2% 71.3% 68.0% 74.3% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 0/15 (0%) 1/13 (8%) |11/19 (58%) 13/17 (77%) 16/21 (76%) 7/11 (64%) |
|FIRST INCIDENCE | --- 660 601 422 |497 422 339 418 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.516 P=0.217 P=0.150 P=0.240 |P=0.018 * P=0.173 P=0.391 P=0.025 * |
|POLY 3 | P=0.521 P=0.222 P=0.125 P=0.230 |P=0.184 P=0.152 P=0.252 P=0.090 |
|POLY 1.5 | P=0.524 P=0.226 P=0.122 P=0.233 |P=0.223 P=0.178 P=0.280 P=0.122 |
|POLY 6 | P=0.519 P=0.219 P=0.131 P=0.228 |P=0.158 P=0.128 P=0.223 P=0.069 |
|LOGISTIC REGRESSION| P=0.524 P=0.217 P=0.122 P=0.266 |P=0.172 P=0.172 P=0.264 P=0.096 |
|COCH-ARM / FISHERS | P=0.527 P=0.247 P=0.121 P=0.247 |P=0.329 P=0.210 P=0.344 P=0.210 |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 11
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 3/50 (6%) 3/50 (6%) |29/50 (58%) 32/50 (64%) 31/50 (62%) 32/50 (64%) |
|POLY-3 ADJUSTED (b)| 0.0% 5.8% 7.9% 8.4% |65.4% 72.7% 72.7% 76.0% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 0/15 (0%) 1/13 (8%) |12/19 (63%) 13/17 (77%) 18/21 (86%) 7/11 (64%) |
|FIRST INCIDENCE | --- 660 601 422 |497 422 339 418 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.278 P=0.217 P=0.150 P=0.119 |P=0.026 * P=0.269 P=0.453 P=0.045 * |
|POLY 3 | P=0.283 P=0.222 P=0.125 P=0.113 |P=0.264 P=0.295 P=0.295 P=0.183 |
|POLY 1.5 | P=0.286 P=0.226 P=0.122 P=0.115 |P=0.307 P=0.319 P=0.337 P=0.228 |
|POLY 6 | P=0.282 P=0.219 P=0.131 P=0.112 |P=0.240 P=0.267 P=0.240 P=0.152 |
|LOGISTIC REGRESSION| P=0.284 P=0.217 P=0.122 P=0.132 |P=0.232 P=0.296 P=0.312 P=0.171 |
|COCH-ARM / FISHERS | P=0.288 P=0.247 P=0.121 P=0.121 |P=0.423 P=0.341 P=0.419 P=0.341 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Gingiva) |
| Papilloma Squamous or Papilloma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 3/50 (6%) 1/50 (2%) 2/50 (4%) |1/50 (2%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 2.7% 8.5% 2.7% 5.7% |2.5% 0.0% 2.7% 0.0% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | 662 524 702 702 |699 --- 734 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.584 P=0.272 P=0.738N P=0.494 |P=0.594N P=0.500N P=0.758 P=0.563N |
|POLY 3 | P=0.572 P=0.286 P=0.757N P=0.481 |P=0.520N P=0.507N P=0.747 P=0.528N |
|POLY 1.5 | P=0.581 P=0.291 P=0.759N P=0.488 |P=0.512N P=0.504N P=0.751 P=0.517N |
|POLY 6 | P=0.561 P=0.284 P=0.754N P=0.474 |P=0.532N P=0.510N P=0.745 P=0.541N |
|LOGISTIC REGRESSION| P=0.586 P=0.307 P=0.757N P=0.476 |P=0.553N P=0.507N P=0.749 P=0.537N |
|COCH-ARM / FISHERS | P=0.595 P=0.309 P=0.753N P=0.500 |P=0.497N P=0.500N P=0.753N P=0.500N |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 12
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Gingiva) |
| Squamous Cell Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |0/50 (0%) 2/50 (4%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 2.7% 0.0% 0.0% 0.0% |0.0% 5.2% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 506 --- --- --- |--- 695 --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.661N P=0.513N P=0.508N P=0.508N |P=0.499N P=0.244 (e) (e) |
|POLY 3 | P=0.660N P=0.518N P=0.499N P=0.514N |P=0.463N P=0.231 (e) (e) |
|POLY 1.5 | P=0.659N P=0.512N P=0.500N P=0.508N |P=0.454N P=0.234 (e) (e) |
|POLY 6 | P=0.662N P=0.524N P=0.497N P=0.519N |P=0.473N P=0.230 (e) (e) |
|LOGISTIC REGRESSION| P=0.667N P=0.403N P=0.521N P=0.437N |P=0.476N P=0.230 (e) (e) |
|COCH-ARM / FISHERS | P=0.660N P=0.500N P=0.500N P=0.500N |P=0.443N P=0.247 (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Gingiva) |
| Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 3/50 (6%) 1/50 (2%) 2/50 (4%) |1/50 (2%) 2/50 (4%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 5.3% 8.5% 2.7% 5.7% |2.5% 5.2% 2.7% 0.0% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | 506 524 702 702 |699 695 734 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.631N P=0.457 P=0.482N P=0.684 |P=0.336N P=0.504 P=0.758 P=0.563N |
|POLY 3 | P=0.650N P=0.469 P=0.499N P=0.669 |P=0.288N P=0.491 P=0.747 P=0.528N |
|POLY 1.5 | P=0.637N P=0.478 P=0.500N P=0.679 |P=0.276N P=0.495 P=0.751 P=0.517N |
|POLY 6 | P=0.642 P=0.463 P=0.497N P=0.659 |P=0.303N P=0.488 P=0.745 P=0.541N |
|LOGISTIC REGRESSION| P=0.624N P=0.538 P=0.507N P=0.691 |P=0.299N P=0.488 P=0.749 P=0.537N |
|COCH-ARM / FISHERS | P=0.622N P=0.500 P=0.500N P=0.691N |P=0.258N P=0.500 P=0.753N P=0.500N |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 13
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Oral Mucosa |
| Squamous Cell Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |0/50 (0%) 2/50 (4%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |0.0% 5.2% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | --- --- --- --- |--- 695 --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.499N P=0.244 (e) (e) |
|POLY 3 | (e) (e) (e) (e) |P=0.463N P=0.231 (e) (e) |
|POLY 1.5 | (e) (e) (e) (e) |P=0.454N P=0.234 (e) (e) |
|POLY 6 | (e) (e) (e) (e) |P=0.473N P=0.230 (e) (e) |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.476N P=0.230 (e) (e) |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.443N P=0.247 (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Oral Mucosa |
| Squamous Cell Papilloma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 3/50 (6%) 0/50 (0%) 1/50 (2%) |1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 8.5% 0.0% 2.9% |2.5% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | --- 524 --- 733 (T) |699 --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.692N P=0.114 (e) P=0.500 |P=0.714N P=0.500N P=0.524N P=0.563N |
|POLY 3 | P=0.698N P=0.109 (e) P=0.490 |P=0.663N P=0.507N P=0.512N P=0.528N |
|POLY 1.5 | P=0.689N P=0.112 (e) P=0.494 |P=0.661N P=0.504N P=0.509N P=0.517N |
|POLY 6 | P=0.705N P=0.109 (e) P=0.487 |P=0.666N P=0.510N P=0.515N P=0.541N |
|LOGISTIC REGRESSION| P=0.675N P=0.124 (e) P=0.500 |P=0.689N P=0.507N P=0.512N P=0.537N |
|COCH-ARM / FISHERS | P=0.672N P=0.121 (e) P=0.500 |P=0.660N P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 14
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Pancreas |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/49 (4%) 1/49 (2%) 1/50 (2%) 1/50 (2%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/49 (0%) |
|POLY-3 ADJUSTED (b)| 5.5% 2.9% 2.7% 2.9% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/13 (8%) 0/13 (0%) 1/15 (7%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 720 712 733 (T) 732 |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.584N P=0.538N P=0.460N P=0.507N |(e) (e) (e) (e) |
|POLY 3 | P=0.582N P=0.520N P=0.487N P=0.513N |(e) (e) (e) (e) |
|POLY 1.5 | P=0.575N P=0.513N P=0.490N P=0.505N |(e) (e) (e) (e) |
|POLY 6 | P=0.590N P=0.526N P=0.481N P=0.521N |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.589N P=0.528N P=0.472N P=0.512N |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.568N P=0.500N P=0.492N P=0.492N |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 21/49 (43%) 22/49 (45%) 21/50 (42%) 19/50 (38%) |42/50 (84%) 43/50 (86%) 36/50 (72%) 31/49 (63%) |
|POLY-3 ADJUSTED (b)| 49.6% 56.8% 50.9% 48.8% |92.3% 94.8% 81.3% 74.8% |
|TERMINAL (d) | 4/13 (31%) 7/13 (54%) 7/15 (47%) 7/13 (54%) |19/19 (100%) 17/17 (100%) 19/21 (91%) 9/11 (82%) |
|FIRST INCIDENCE | 338 574 513 539 |581 478 339 506 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.439N P=0.418 P=0.459N P=0.504N |P=0.451 P=0.339 P=0.208N P=0.479 |
|POLY 3 | P=0.414N P=0.328 P=0.539 P=0.564N |P=0.004N** P=0.470 P=0.081N P=0.014N* |
|POLY 1.5 | P=0.365N P=0.383 P=0.567 P=0.494N |P=0.005N** P=0.497 P=0.094N P=0.015N* |
|POLY 6 | P=0.478N P=0.283 P=0.510 P=0.555 |P=0.002N** P=0.437 P=0.068N P=0.013N* |
|LOGISTIC REGRESSION| P=0.344N P=0.464 P=0.541N P=0.407N |P=0.028N* P=0.238 P=0.204N P=0.068N |
|COCH-ARM / FISHERS | P=0.305N P=0.500 P=0.547N P=0.387N |P=0.007N** P=0.500 P=0.114N P=0.017N* |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 15
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Prostate |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/48 (4%) 0/50 (0%) 0/50 (0%) | |
|POLY-3 ADJUSTED (b)| 0.0% 5.9% 0.0% 0.0% | |
|TERMINAL (d) | 0/13 (0%) 2/13 (15%) 0/15 (0%) 0/13 (0%) | |
|FIRST INCIDENCE | --- 733 (T) --- --- | |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.451N P=0.235 (e) (e) | |
|POLY 3 | P=0.459N P=0.220 (e) (e) | |
|POLY 1.5 | P=0.451N P=0.223 (e) (e) | |
|POLY 6 | P=0.468N P=0.215 (e) (e) | |
|LOGISTIC REGRESSION| (e) P=0.235 (e) (e) | |
|COCH-ARM / FISHERS | P=0.439N P=0.237 (e) (e) | |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Basal Cell Adenoma, Basosquamous Tumor Benign, or |
| Trichoepithelioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 0/50 (0%) 2/50 (4%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 2.7% 0.0% 0.0% 5.7% |0.0% 0.0% 0.0% 2.9% |
|TERMINAL (d) | 1/13 (8%) 0/13 (0%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 1/11 (9%) |
|FIRST INCIDENCE | 733 (T) --- --- 702 |--- --- --- 734 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.158 P=0.500N P=0.471N P=0.513 |P=0.159 (e) (e) P=0.391 |
|POLY 3 | P=0.156 P=0.514N P=0.495N P=0.483 |P=0.239 (e) (e) P=0.473 |
|POLY 1.5 | P=0.158 P=0.510N P=0.498N P=0.489 |P=0.245 (e) (e) P=0.483 |
|POLY 6 | P=0.154 P=0.518N P=0.491N P=0.479 |P=0.231 (e) (e) P=0.461 |
|LOGISTIC REGRESSION| P=0.147 (e) (e) P=0.483 |(e) (e) (e) P=0.391 |
|COCH-ARM / FISHERS | P=0.160 P=0.500N P=0.500N P=0.500 |P=0.257 (e) (e) P=0.500 |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 16
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Basal Cell Carcinoma, Basal Cell Adenoma, Basosquamous |
| Tumor (benign, malignant or NOS), or Trichoepithelioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 0/50 (0%) 2/50 (4%) |0/50 (0%) 0/50 (0%) 1/50 (2%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 2.7% 0.0% 0.0% 5.7% |0.0% 0.0% 2.7% 2.9% |
|TERMINAL (d) | 1/13 (8%) 0/13 (0%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 1/11 (9%) |
|FIRST INCIDENCE | 733 (T) --- --- 702 |--- --- 734 (T) 734 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.158 P=0.500N P=0.471N P=0.513 |P=0.302 (e) P=0.520 P=0.391 |
|POLY 3 | P=0.156 P=0.514N P=0.495N P=0.483 |P=0.399 (e) P=0.488 P=0.473 |
|POLY 1.5 | P=0.158 P=0.510N P=0.498N P=0.489 |P=0.412 (e) P=0.491 P=0.483 |
|POLY 6 | P=0.154 P=0.518N P=0.491N P=0.479 |P=0.384 (e) P=0.487 P=0.461 |
|LOGISTIC REGRESSION| P=0.147 (e) (e) P=0.483 |(e) (e) P=0.520 P=0.391 |
|COCH-ARM / FISHERS | P=0.160 P=0.500N P=0.500N P=0.500 |P=0.436 (e) P=0.500 P=0.500 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor |
| (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepitheliom |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 4/50 (8%) 5/50 (10%) 6/50 (12%) |0/50 (0%) 0/50 (0%) 2/50 (4%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 10.9% 11.4% 13.3% 16.5% |0.0% 0.0% 5.4% 2.9% |
|TERMINAL (d) | 3/13 (23%) 2/13 (15%) 3/15 (20%) 2/13 (15%) |0/19 (0%) 0/17 (0%) 2/21 (10%) 1/11 (9%) |
|FIRST INCIDENCE | 671 594 702 519 |--- --- 734 (T) 734 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.295 P=0.617 P=0.582 P=0.354 |P=0.393 (e) P=0.259 P=0.391 |
|POLY 3 | P=0.317 P=0.616 P=0.514 P=0.358 |P=0.498 (e) P=0.224 P=0.473 |
|POLY 1.5 | P=0.318 P=0.622 P=0.507 P=0.360 |P=0.514 (e) P=0.227 P=0.483 |
|POLY 6 | P=0.321 P=0.619 P=0.527 P=0.364 |P=0.478 (e) P=0.221 P=0.461 |
|LOGISTIC REGRESSION| P=0.284 P=0.596 P=0.550 P=0.334 |(e) (e) P=0.259 P=0.391 |
|COCH-ARM / FISHERS | P=0.319 P=0.643N P=0.500 P=0.370 |P=0.546 (e) P=0.247 P=0.500 |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 17
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Fibroma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 1/50 (2%) 2/50 (4%) 1/50 (2%) |1/50 (2%) 0/50 (0%) 2/50 (4%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 8.0% 2.9% 5.3% 2.8% |2.5% 0.0% 5.3% 2.9% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 1/15 (7%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | 566 733 (T) 674 618 |607 --- 684 709 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.420N P=0.337N P=0.474N P=0.336N |P=0.587 P=0.516N P=0.484 P=0.698 |
|POLY 3 | P=0.404N P=0.340N P=0.499N P=0.328N |P=0.624 P=0.508N P=0.477 P=0.728 |
|POLY 1.5 | P=0.400N P=0.328N P=0.500N P=0.319N |P=0.639 P=0.504N P=0.484 P=0.741 |
|POLY 6 | P=0.408N P=0.354N P=0.497N P=0.338N |P=0.605 P=0.512N P=0.473 P=0.712 |
|LOGISTIC REGRESSION| P=0.405N P=0.316N P=0.499N P=0.291N |P=0.642 P=0.496N P=0.489 P=0.757 |
|COCH-ARM / FISHERS | P=0.398N P=0.309N P=0.500N P=0.309N |P=0.668 P=0.500N P=0.500 P=0.753N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, |
| or Fibrous Histiocytoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 2/50 (4%) 4/50 (8%) 1/50 (2%) |1/50 (2%) 0/50 (0%) 3/50 (6%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 8.0% 5.8% 10.6% 2.8% |2.5% 0.0% 8.0% 2.9% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 3/15 (20%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | 566 548 674 618 |607 --- 647 709 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.264N P=0.530N P=0.544 P=0.336N |P=0.643 P=0.516N P=0.286 P=0.698 |
|POLY 3 | P=0.253N P=0.538N P=0.501 P=0.328N |P=0.672 P=0.508N P=0.284 P=0.728 |
|POLY 1.5 | P=0.247N P=0.526N P=0.500 P=0.319N |P=0.683N P=0.504N P=0.290 P=0.741 |
|POLY 6 | P=0.259N P=0.551N P=0.503 P=0.338N |P=0.651 P=0.512N P=0.282 P=0.712 |
|LOGISTIC REGRESSION| P=0.249N P=0.493N P=0.514 P=0.291N |P=0.682N P=0.496N P=0.297 P=0.757 |
|COCH-ARM / FISHERS | P=0.242N P=0.500N P=0.500 P=0.309N |P=0.652N P=0.500N P=0.309 P=0.753N |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 18
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Fibrosarcoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 2/50 (4%) 0/50 (0%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.9% 5.3% 0.0% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 2/15 (13%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | --- 548 733 (T) --- |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.420N P=0.495 P=0.268 (e) |(e) (e) (e) (e) |
|POLY 3 | P=0.417N P=0.489 P=0.241 (e) |(e) (e) (e) (e) |
|POLY 1.5 | P=0.412N P=0.492 P=0.239 (e) |(e) (e) (e) (e) |
|POLY 6 | P=0.422N P=0.488 P=0.245 (e) |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.412N P=0.561 P=0.268 (e) |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.405N P=0.500 P=0.247 (e) |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 2/50 (4%) 0/50 (0%) |0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.9% 5.3% 0.0% |0.0% 0.0% 2.7% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 2/15 (13%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | --- 548 733 (T) --- |--- --- 647 --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.420N P=0.495 P=0.268 (e) |P=0.771N (e) P=0.477 (e) |
|POLY 3 | P=0.417N P=0.489 P=0.241 (e) |P=0.761N (e) P=0.490 (e) |
|POLY 1.5 | P=0.412N P=0.492 P=0.239 (e) |P=0.754N (e) P=0.492 (e) |
|POLY 6 | P=0.422N P=0.488 P=0.245 (e) |P=0.769N (e) P=0.490 (e) |
|LOGISTIC REGRESSION| P=0.412N P=0.561 P=0.268 (e) |P=0.744N (e) P=0.503 (e) |
|COCH-ARM / FISHERS | P=0.405N P=0.500 P=0.247 (e) |P=0.743N (e) P=0.500 (e) |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 19
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Keratoacanthoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 2/50 (4%) 4/50 (8%) 3/50 (6%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 8.1% 5.8% 10.6% 8.4% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/13 (15%) 1/13 (8%) 2/15 (13%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 671 621 702 519 |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.580 P=0.527N P=0.568 P=0.642 |(e) (e) (e) (e) |
|POLY 3 | P=0.603 P=0.531N P=0.512 P=0.652 |(e) (e) (e) (e) |
|POLY 1.5 | P=0.602 P=0.522N P=0.506 P=0.654 |(e) (e) (e) (e) |
|POLY 6 | P=0.606 P=0.537N P=0.523 P=0.654 |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.578 P=0.541N P=0.542 P=0.646 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.601 P=0.500N P=0.500 P=0.661N |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Papilloma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 1/50 (2%) 1/50 (2%) |0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 5.8% 2.7% 2.8% |0.0% 0.0% 2.7% 0.0% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 1/15 (7%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | --- 594 733 (T) 621 |--- --- 734 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.693 P=0.228 P=0.529 P=0.475 |P=0.841N (e) P=0.520 (e) |
|POLY 3 | P=0.690 P=0.223 P=0.505 P=0.492 |P=0.761N (e) P=0.488 (e) |
|POLY 1.5 | P=0.694 P=0.227 P=0.502 P=0.495 |P=0.754N (e) P=0.491 (e) |
|POLY 6 | P=0.688 P=0.221 P=0.509 P=0.491 |P=0.769N (e) P=0.487 (e) |
|LOGISTIC REGRESSION| P=0.696 P=0.226 P=0.529 P=0.509 |(e) (e) P=0.520 (e) |
|COCH-ARM / FISHERS | P=0.702 P=0.247 P=0.500 P=0.500 |P=0.743N (e) P=0.500 (e) |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 20
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Papilloma, Papilloma, Squamous Cell |
| Carcinoma or Keratoacanthoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 4/50 (8%) 5/50 (10%) 4/50 (8%) |0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 8.1% 11.4% 13.3% 11.0% |0.0% 0.0% 2.7% 0.0% |
|TERMINAL (d) | 2/13 (15%) 2/13 (15%) 3/15 (20%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | 671 594 702 519 |--- --- 734 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.561 P=0.468 P=0.428 P=0.471 |P=0.841N (e) P=0.520 (e) |
|POLY 3 | P=0.587 P=0.471 P=0.366 P=0.491 |P=0.761N (e) P=0.488 (e) |
|POLY 1.5 | P=0.586 P=0.477 P=0.361 P=0.492 |P=0.754N (e) P=0.491 (e) |
|POLY 6 | P=0.594 P=0.470 P=0.374 P=0.497 |P=0.769N (e) P=0.487 (e) |
|LOGISTIC REGRESSION| P=0.561 P=0.454 P=0.393 P=0.484 |(e) (e) P=0.520 (e) |
|COCH-ARM / FISHERS | P=0.586 P=0.500 P=0.357 P=0.500 |P=0.743N (e) P=0.500 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Papilloma, Papilloma, or Keratoacanthoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 4/50 (8%) 5/50 (10%) 4/50 (8%) |0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 8.1% 11.4% 13.3% 11.0% |0.0% 0.0% 2.7% 0.0% |
|TERMINAL (d) | 2/13 (15%) 2/13 (15%) 3/15 (20%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | 671 594 702 519 |--- --- 734 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.561 P=0.468 P=0.428 P=0.471 |P=0.841N (e) P=0.520 (e) |
|POLY 3 | P=0.587 P=0.471 P=0.366 P=0.491 |P=0.761N (e) P=0.488 (e) |
|POLY 1.5 | P=0.586 P=0.477 P=0.361 P=0.492 |P=0.754N (e) P=0.491 (e) |
|POLY 6 | P=0.594 P=0.470 P=0.374 P=0.497 |P=0.769N (e) P=0.487 (e) |
|LOGISTIC REGRESSION| P=0.561 P=0.454 P=0.393 P=0.484 |(e) (e) P=0.520 (e) |
|COCH-ARM / FISHERS | P=0.586 P=0.500 P=0.357 P=0.500 |P=0.743N (e) P=0.500 (e) |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 21
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Testes |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 45/50 (90%) 40/50 (80%) 46/50 (92%) 41/50 (82%) | |
|POLY-3 ADJUSTED (b)| 95.5% 90.1% 95.5% 90.9% | |
|TERMINAL (d) | 13/13 (100%) 12/13 (92%) 15/15 (100%) 13/13 (100%)| |
|FIRST INCIDENCE | 506 524 394 422 | |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.516N P=0.443N P=0.409N P=0.465N | |
|POLY 3 | P=0.345N P=0.227N P=0.742N P=0.269N | |
|POLY 1.5 | P=0.284N P=0.199N P=0.643 P=0.228N | |
|POLY 6 | P=0.473N P=0.237N P=0.841N P=0.357N | |
|LOGISTIC REGRESSION| P=0.321N P=0.314N P=0.511 P=0.337N | |
|COCH-ARM / FISHERS | P=0.267N P=0.131N P=0.500 P=0.194N | |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/46 (7%) 5/46 (11%) 6/49 (12%) 2/50 (4%) |7/50 (14%) 4/49 (8%) 4/48 (8%) 1/49 (2%) |
|POLY-3 ADJUSTED (b)| 8.7% 14.6% 15.5% 5.7% |17.5% 10.5% 10.8% 2.9% |
|TERMINAL (d) | 1/13 (8%) 1/13 (8%) 2/15 (13%) 0/13 (0%) |3/19 (16%) 2/17 (12%) 2/21 (10%) 0/11 (0%) |
|FIRST INCIDENCE | 645 393 562 645 |677 700 630 703 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.227N P=0.334 P=0.290 P=0.523N |P=0.137N P=0.300N P=0.271N P=0.101N |
|POLY 3 | P=0.202N P=0.350 P=0.299 P=0.489N |P=0.078N P=0.286N P=0.306N P=0.048N* |
|POLY 1.5 | P=0.189N P=0.351 P=0.287 P=0.478N |P=0.069N P=0.280N P=0.302N P=0.042N* |
|POLY 6 | P=0.217N P=0.350 P=0.318 P=0.501N |P=0.091N P=0.293N P=0.306N P=0.058N |
|LOGISTIC REGRESSION| P=0.179N P=0.347 P=0.278 P=0.502N |P=0.086N P=0.283N P=0.312N P=0.062N |
|COCH-ARM / FISHERS | P=0.172N P=0.357 P=0.276 P=0.460N |P=0.057N P=0.274N P=0.286N P=0.032N* |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 22
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/46 (0%) 3/46 (7%) 2/49 (4%) 1/50 (2%) |2/50 (4%) 1/49 (2%) 2/48 (4%) 3/49 (6%) |
|POLY-3 ADJUSTED (b)| 0.0% 9.0% 5.4% 2.8% |5.0% 2.6% 5.5% 8.7% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 0/15 (0%) 0/13 (0%) |1/19 (5%) 1/17 (6%) 1/21 (5%) 1/11 (9%) |
|FIRST INCIDENCE | --- 614 660 615 |684 734 (T) 605 632 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.530N P=0.110 P=0.258 P=0.482 |P=0.179 P=0.518N P=0.692 P=0.353 |
|POLY 3 | P=0.503N P=0.112 P=0.257 P=0.507 |P=0.275 P=0.516N P=0.667 P=0.436 |
|POLY 1.5 | P=0.493N P=0.114 P=0.254 P=0.510 |P=0.291 P=0.512N P=0.669 P=0.455 |
|POLY 6 | P=0.513N P=0.111 P=0.261 P=0.503 |P=0.258 P=0.520N P=0.667 P=0.415 |
|LOGISTIC REGRESSION| P=0.498N P=0.112 P=0.257 P=0.529 |P=0.260 P=0.515N P=0.667 P=0.417 |
|COCH-ARM / FISHERS | P=0.477N P=0.121 P=0.263 P=0.521 |P=0.320 P=0.508N P=0.676 P=0.490 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/46 (7%) 8/46 (17%) 8/49 (16%) 3/50 (6%) |9/50 (18%) 5/49 (10%) 6/48 (13%) 4/49 (8%) |
|POLY-3 ADJUSTED (b)| 8.7% 23.0% 20.5% 8.4% |22.4% 13.1% 16.1% 11.6% |
|TERMINAL (d) | 1/13 (8%) 2/13 (15%) 2/15 (13%) 0/13 (0%) |4/19 (21%) 3/17 (18%) 3/21 (14%) 1/11 (9%) |
|FIRST INCIDENCE | 645 393 562 615 |677 700 605 632 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.201N P=0.093 P=0.139 P=0.633 |P=0.456N P=0.232N P=0.299N P=0.316N |
|POLY 3 | P=0.161N P=0.093 P=0.136 P=0.649N |P=0.277N P=0.218N P=0.338N P=0.176N |
|POLY 1.5 | P=0.151N P=0.094 P=0.128 P=0.639N |P=0.252N P=0.211N P=0.335N P=0.156N |
|POLY 6 | P=0.173N P=0.092 P=0.151 P=0.658N |P=0.308N P=0.226N P=0.336N P=0.202N |
|LOGISTIC REGRESSION| P=0.148N P=0.091 P=0.124 P=0.656N |P=0.309N P=0.211N P=0.351N P=0.210N |
|COCH-ARM / FISHERS | P=0.137N P=0.099 P=0.120 P=0.621N |P=0.211N P=0.205N P=0.318N P=0.125N |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 23
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/46 (2%) 0/46 (0%) 0/49 (0%) 0/50 (0%) |2/50 (4%) 0/49 (0%) 0/48 (0%) 1/49 (2%) |
|POLY-3 ADJUSTED (b)| 2.9% 0.0% 0.0% 0.0% |5.0% 0.0% 0.0% 2.9% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |1/19 (5%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 688 --- --- --- |660 --- --- 631 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.662N P=0.490N P=0.471N P=0.490N |P=0.596 P=0.262N P=0.242N P=0.597N |
|POLY 3 | P=0.653N P=0.508N P=0.484N P=0.497N |P=0.630 P=0.247N P=0.257N P=0.551N |
|POLY 1.5 | P=0.650N P=0.505N P=0.486N P=0.491N |P=0.637 P=0.245N P=0.254N P=0.535N |
|POLY 6 | P=0.656N P=0.513N P=0.483N P=0.504N |P=0.621 P=0.250N P=0.260N P=0.569N |
|LOGISTIC REGRESSION| P=0.662N P=0.509N P=0.482N P=0.500N |P=0.636 P=0.247N P=0.256N P=0.538N |
|COCH-ARM / FISHERS | P=0.647N P=0.500N P=0.484N P=0.479N |P=0.652 P=0.253N P=0.258N P=0.508N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/46 (2%) 0/46 (0%) 0/49 (0%) 0/50 (0%) |2/50 (4%) 1/49 (2%) 1/48 (2%) 2/49 (4%) |
|POLY-3 ADJUSTED (b)| 2.9% 0.0% 0.0% 0.0% |5.0% 2.6% 2.8% 5.8% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |1/19 (5%) 1/17 (6%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | 688 --- --- --- |660 734 (T) 734 (T) 631 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.662N P=0.490N P=0.471N P=0.490N |P=0.372 P=0.536N P=0.491N P=0.600 |
|POLY 3 | P=0.653N P=0.508N P=0.484N P=0.497N |P=0.461 P=0.517N P=0.532N P=0.643 |
|POLY 1.5 | P=0.650N P=0.505N P=0.486N P=0.491N |P=0.475 P=0.512N P=0.527N P=0.658 |
|POLY 6 | P=0.656N P=0.513N P=0.483N P=0.504N |P=0.446 P=0.522N P=0.537N P=0.626 |
|LOGISTIC REGRESSION| P=0.662N P=0.509N P=0.482N P=0.500N |P=0.443 P=0.516N P=0.531N P=0.654 |
|COCH-ARM / FISHERS | P=0.647N P=0.500N P=0.484N P=0.479N |P=0.501 P=0.508N P=0.515N P=0.684 |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 24
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Tongue |
| Squamous Cell Carcinoma or Papilloma Squamous |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 1/50 (2%) 1/50 (2%) |0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 5.3% 0.0% 2.7% 2.9% |0.0% 0.0% 2.7% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 1/21 (5%) 0/11 (0%) |
|FIRST INCIDENCE | 506 --- 702 702 |--- --- 734 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.698N P=0.275N P=0.482N P=0.510N |P=0.841N (e) P=0.520 (e) |
|POLY 3 | P=0.704N P=0.258N P=0.499N P=0.525N |P=0.761N (e) P=0.488 (e) |
|POLY 1.5 | P=0.702N P=0.251N P=0.500N P=0.515N |P=0.754N (e) P=0.491 (e) |
|POLY 6 | P=0.708N P=0.266N P=0.497N P=0.536N |P=0.769N (e) P=0.487 (e) |
|LOGISTIC REGRESSION| P=0.702N P=0.196N P=0.507N P=0.486N |(e) (e) P=0.520 (e) |
|COCH-ARM / FISHERS | P=0.702N P=0.247N P=0.500N P=0.500N |P=0.743N (e) P=0.500 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | |7/50 (14%) 6/50 (12%) 6/50 (12%) 2/50 (4%) |
|POLY-3 ADJUSTED (b)| |17.4% 15.1% 15.6% 5.7% |
|TERMINAL (d) | |3/19 (16%) 1/17 (6%) 3/21 (14%) 1/11 (9%) |
|FIRST INCIDENCE | |589 585 534 422 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.164N P=0.533N P=0.494N P=0.210N |
|POLY 3 | |P=0.098N P=0.512N P=0.536N P=0.111N |
|POLY 1.5 | |P=0.085N P=0.507N P=0.528N P=0.098N |
|POLY 6 | |P=0.121N P=0.510N P=0.538N P=0.131N |
|LOGISTIC REGRESSION| |P=0.080N P=0.517N P=0.537N P=0.100N |
|COCH-ARM / FISHERS | |P=0.067N P=0.500N P=0.500N P=0.080N |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 25
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Hemangioma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 2/50 (4%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 5.7% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | --- --- --- 668 |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.042 * (e) (e) P=0.224 |(e) (e) (e) (e) |
|POLY 3 | P=0.043 * (e) (e) P=0.227 |(e) (e) (e) (e) |
|POLY 1.5 | P=0.044 * (e) (e) P=0.230 |(e) (e) (e) (e) |
|POLY 6 | P=0.043 * (e) (e) P=0.225 |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.041 * (e) (e) P=0.223 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.046 * (e) (e) P=0.247 |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 1/50 (2%) 2/50 (4%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 2.7% 5.7% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | --- --- 678 668 |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.119 (e) P=0.508 P=0.224 |(e) (e) (e) (e) |
|POLY 3 | P=0.126 (e) P=0.506 P=0.227 |(e) (e) (e) (e) |
|POLY 1.5 | P=0.127 (e) P=0.503 P=0.230 |(e) (e) (e) (e) |
|POLY 6 | P=0.126 (e) P=0.511 P=0.225 |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.118 (e) P=0.505 P=0.223 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.128 (e) P=0.500 P=0.247 |(e) (e) (e) (e) |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 26
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Histiocytic Sarcoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |0/50 (0%) 2/50 (4%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 2.6% 0.0% |0.0% 5.1% 2.7% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 0/13 (0%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | --- --- 443 --- |--- 559 678 --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.746N (e) P=0.500 (e) |P=0.396N P=0.223 P=0.465 (e) |
|POLY 3 | P=0.745N (e) P=0.509 (e) |P=0.390N P=0.236 P=0.489 (e) |
|POLY 1.5 | P=0.743N (e) P=0.505 (e) |P=0.377N P=0.237 P=0.492 (e) |
|POLY 6 | P=0.746N (e) P=0.515 (e) |P=0.405N P=0.237 P=0.489 (e) |
|LOGISTIC REGRESSION| P=0.769N (e) P=0.454 (e) |P=0.327N P=0.236 P=0.493 (e) |
|COCH-ARM / FISHERS | P=0.743N (e) P=0.500 (e) |P=0.358N P=0.247 P=0.500 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Leukemia: Lymphocytic, Monocytic, Mononuclear, or |
| Undifferentiated |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 19/50 (38%) 28/50 (56%) 33/50 (66%) 28/50 (56%) |22/50 (44%) 21/50 (42%) 18/50 (36%) 33/50 (66%) |
|POLY-3 ADJUSTED (b)| 45.6% 65.9% 73.1% 66.4% |51.7% 48.2% 42.2% 73.7% |
|TERMINAL (d) | 4/13 (31%) 7/13 (54%) 12/15 (80%) 7/13 (54%) |11/19 (58%) 5/17 (29%) 5/21 (24%) 6/11 (55%) |
|FIRST INCIDENCE | 506 350 450 520 |506 497 310 418 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.309 P=0.070 P=0.047 * P=0.077 |P<0.001 ** P=0.540 P=0.317N P=0.003 ** |
|POLY 3 | P=0.288 P=0.038 * P=0.004 ** P=0.034 * |P<0.001 ** P=0.456N P=0.248N P=0.021 * |
|POLY 1.5 | P=0.306 P=0.040 * P=0.004 ** P=0.039 * |P<0.001 ** P=0.475N P=0.263N P=0.017 * |
|POLY 6 | P=0.294 P=0.039 * P=0.006 ** P=0.036 * |P=0.002 ** P=0.417N P=0.221N P=0.033 * |
|LOGISTIC REGRESSION| P=0.327 P=0.047 * P=0.005 ** P=0.043 * |P=0.002 ** P=0.520N P=0.290N P=0.012 * |
|COCH-ARM / FISHERS | P=0.347 P=0.054 P=0.004 ** P=0.054 |P=0.002 ** P=0.500N P=0.270N P=0.022 * |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 27
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Mesothelioma: Benign, Malignant, NOS |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 1/50 (2%) 1/50 (2%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 5.3% 5.8% 2.7% 2.9% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 1/13 (8%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 599 534 680 733 (T) |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.489N P=0.659 P=0.484N P=0.523N |(e) (e) (e) (e) |
|POLY 3 | P=0.485N P=0.668 P=0.497N P=0.525N |(e) (e) (e) (e) |
|POLY 1.5 | P=0.475N P=0.676 P=0.499N P=0.515N |(e) (e) (e) (e) |
|POLY 6 | P=0.498N P=0.661 P=0.495N P=0.538N |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.466N P=0.686N P=0.503N P=0.509N |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.463N P=0.691N P=0.500N P=0.500N |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Osteosarcoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 2/50 (4%) 1/50 (2%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 2.7% 0.0% 5.2% 2.9% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 567 --- 562 733 (T) |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.643 P=0.510N P=0.512 P=0.752 |(e) (e) (e) (e) |
|POLY 3 | P=0.666 P=0.517N P=0.511 P=0.747 |(e) (e) (e) (e) |
|POLY 1.5 | P=0.668 P=0.512N P=0.506 P=0.752 |(e) (e) (e) (e) |
|POLY 6 | P=0.663 P=0.523N P=0.521 P=0.742 |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.671 P=0.454N P=0.489 P=0.761 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.668 P=0.500N P=0.500 P=0.753N |(e) (e) (e) (e) |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 28
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Osteosarcoma or Osteoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 2/50 (4%) 1/50 (2%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 2.7% 0.0% 5.2% 2.9% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/13 (0%) 0/13 (0%) 0/15 (0%) 1/13 (8%) |0/19 (0%) 0/17 (0%) 0/21 (0%) 0/11 (0%) |
|FIRST INCIDENCE | 567 --- 562 733 (T) |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.643 P=0.510N P=0.512 P=0.752 |(e) (e) (e) (e) |
|POLY 3 | P=0.666 P=0.517N P=0.511 P=0.747 |(e) (e) (e) (e) |
|POLY 1.5 | P=0.668 P=0.512N P=0.506 P=0.752 |(e) (e) (e) (e) |
|POLY 6 | P=0.663 P=0.523N P=0.521 P=0.742 |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.671 P=0.454N P=0.489 P=0.761 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.668 P=0.500N P=0.500 P=0.753N |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 50/50 (100%) 47/50 (94%) 49/50 (98%) 46/50 (92%) |48/50 (96%) 46/50 (92%) 43/50 (86%) 43/50 (86%) |
|POLY-3 ADJUSTED (b)| 100.0% 99.6% 99.1% 96.8% |99.7% 97.7% 93.9% 94.2% |
|TERMINAL (d) | 13/13 (100%) 13/13 (100%) 15/15 (100%) 13/13 (100%)|19/19 (100%) 17/17 (100%) 21/21 (100%) 10/11 (91%) |
|FIRST INCIDENCE | 338 393 394 422 |497 422 339 418 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.518N P=0.531 P=0.319N P=0.488N |P=0.064 P=0.493 P=0.288N P=0.136 |
|POLY 3 | P=0.116N P=1.000N P=0.891N P=0.276N |P=0.205N P=0.533N P=0.104N P=0.123N |
|POLY 1.5 | P=0.073N P=0.700N P=0.689N P=0.141N |P=0.193N P=0.331N P=0.074N P=0.084N |
|POLY 6 | P=0.258N P=1.000N P=1.000N P=0.498N |P=0.215N P=1.000N P=0.179N P=0.211N |
|LOGISTIC REGRESSION| P=0.066N P=0.395N P=0.489N P=0.089N |P=0.459N P=0.331N P=0.164N P=0.247N |
|COCH-ARM / FISHERS | P=0.104N P=0.121N P=0.500N P=0.059N |P=0.164N P=0.339N P=0.080N P=0.080N |
|=================================================================================================================================|
Date: 02/17/99 EXPERIMENT: 05180 TEST: 06 Page 29
Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 30/50 (60%) 38/50 (76%) 41/50 (82%) 34/50 (68%) |28/50 (56%) 28/50 (56%) 32/50 (64%) 38/50 (76%) |
|POLY-3 ADJUSTED (b)| 67.2% 81.8% 85.9% 77.8% |63.9% 61.5% 72.4% 82.6% |
|TERMINAL (d) | 8/13 (62%) 10/13 (77%) 12/15 (80%) 9/13 (69%) |13/19 (68%) 8/17 (47%) 15/21 (71%) 7/11 (64%) |
|FIRST INCIDENCE | 506 204 443 520 |506 478 310 418 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.534N P=0.109 P=0.171 P=0.261 |P<0.001 ** P=0.452 P=0.315 P=0.004 ** |
|POLY 3 | P=0.567 P=0.070 P=0.020 * P=0.171 |P=0.014 * P=0.495N P=0.251 P=0.028 * |
|POLY 1.5 | P=0.521N P=0.065 P=0.015 * P=0.200 |P=0.011 * P=0.530N P=0.250 P=0.021 * |
|POLY 6 | P=0.516 P=0.078 P=0.032 * P=0.159 |P=0.023 * P=0.443N P=0.269 P=0.051 |
|LOGISTIC REGRESSION| P=0.401N P=0.070 P=0.014 * P=0.220 |P=0.010 * P=0.565 P=0.204 P=0.012 * |
|COCH-ARM / FISHERS | P=0.389N P=0.066 P=0.013 * P=0.266 |P=0.017 * P=0.580N P=0.270 P=0.028 * |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.01 0.1 1.0 |CONTROL 0.01 0.1 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # |# # # # |
|----------- | | |
|OVERALL (a) | 50/50 (100%) 49/50 (98%) 50/50 (100%) 48/50 (96%) |48/50 (96%) 49/50 (98%) 49/50 (98%) 47/50 (94%) |
|POLY-3 ADJUSTED (b)| 100.0% 99.9% 100.0% 99.4% |99.7% 99.8% 100.0% 99.7% |
|TERMINAL (d) | 13/13 (100%) 13/13 (100%) 15/15 (100%) 13/13 (100%)|19/19 (100%) 17/17 (100%) 21/21 (100%) 11/11 (100%) |
|FIRST INCIDENCE | 338 204 394 422 |497 422 310 418 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.495 P=0.436 (e) P=0.512 |P=0.041 * P=0.342 P=0.485 P=0.050 |
|POLY 3 | P=0.999N P=1.000N (e) P=1.000N |P=1.000N P=1.000 P=1.000 P=1.000 |
|POLY 1.5 | P=0.506N P=0.996N (e) P=0.705N |P=0.809N P=0.937 P=0.927 P=0.948N |
|POLY 6 | P=1.000N P=1.000N (e) P=1.000N |P=1.000N P=1.000 P=1.000 P=1.000 |
|LOGISTIC REGRESSION| P=0.075N P=0.848N (e) P=0.294N |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.156N P=0.500N (e) P=0.247N |P=0.255N P=0.500 P=0.500 P=0.500N |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Poly-3 adjusted lifetime tumor incidence.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death.
Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fishers exact tests compare directly the overall incidence rates
For all tests a negative trend is indicated by N
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).